Ovarian Cancer Canada

Western Regional Blog – BC, YK, AB, NWT and Nunavut

Survey: Avastin and recurrent ovarian cancer

We understand that the manufacturer of AVASTIN, Hoffman-LaRoche, will be applying for approval from Health Canada in the near future for the use of AVASTIN for women with recurrent ovarian … Continue reading

July 30, 2013

The Children’s Group

A support group program with art activities to help school-aged children 5 -12 years old who have a parent or family member living with cancer. Concurrent session for parents. Saturday … Continue reading

July 30, 2013

Ovarian Cancer Therapies in Development

Cancer Network: Dr. Coleman, I mentioned some of the reasons why ovarian cancer is difficult to treat, but could you discuss this in more detail? Dr. Coleman: One of the … Continue reading

July 24, 2013

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer

BACKGROUND: Ovarian cancer is the eighth most common cancer in women and it is usually diagnosed at an advanced stage. The majority of ovarian tumours are epithelial in origin. Women … Continue reading

July 24, 2013

Recurrence patterns after extended treatment with bevacizumab for ovarian, fallopian tube, and primary peritoneal cancers

Objective To evaluate patterns of recurrence for ovarian, fallopian tube, and primary peritoneal cancer patients undergoing extended treatment with bevacizumab (BEV). Methods A retrospective review of patients with primary ovarian, … Continue reading

July 24, 2013

Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study

Background Few biomarkers of ovarian cancer prognosis have been established, partly because subtype-specific associations might be obscured in studies combining all histopathological subtypes. We examined whether tumour expression of the … Continue reading

July 24, 2013

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer

Background Poly(ADP-ribose) polymerase (PARP)-inhibitors and anti-angiogenics have activity in recurrent ovarian and breast cancer; however, the effect of combined therapy against PARP and angiogenesis in this population has not been … Continue reading

July 24, 2013

Novel Combo of Drugs Shows Promise in Ovarian Cancer

In a first-of-its-kind clinical trial, the combination of the oral antiangiogenic cediranib and the oral poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (both being developed by AstraZeneca) showed promising activity in patients … Continue reading

July 24, 2013

Venous thromboembolism in ovarian cancer: incidence, risk factors and impact on survival

Objectives Ovarian cancer has a higher incidence of venous thromboembolism (VTE) than other cancers. Clear cell cancers carry the highest risk at 11–27%. The aim of this study was to … Continue reading

July 24, 2013

Complementary and Alternative Therapies

CAMEO

Research in BC

The Injustices of Ovarian Cancer

Ovarian Cancer Canada